Drug Trial Radar · NCT06619509
A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine
Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
90
Actual
Start
Dec 30, 2024
Primary completion
Dec 30, 2030
Study completion Dec 30, 2030
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Oct 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults with solid tumours who received at least 4 cycles of treatment with brigimadlin in a previous study. The goal of this study is to find out how well people with solid tumours tolerate long-term treatment with brigimadlin. Brigimadlin is a so-called MDM2 inhibitor that was being developed to treat cancer. All participants take brigimadlin as tablets once every 3 weeks at the study site. At study visits, doctors check participants' health and take note of any unwanted effects. At some study visits, doctors also check the size of the tumour and whether it has spread to other parts of the body. Participants are in the study as long as they benefit from treatment and can tolerate it.
Conditions
- Solid Tumours
Interventions
BrigimadlinDrug
Brigimadlin
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary endpoint will be the occurrence of treatment-emergent adverse events (AEs) according to CTCAE Version 5.0 during the entire treatment periodTime frame: up to 9 years.
Locations
50 sites in 20 countries. Site status is shown where the registry gives one.
Precision NextGen Oncology
Beverly Hills, California
Sarcoma Oncology Center
Santa Monica, California
Yale Cancer Center
New Haven, Connecticut
Mayo Clinic Cancer Center
Jacksonville, Florida
Washington University School of Medicine
St Louis, Missouri
Nebraska Cancer Specialists-Omaha-69066
Omaha, Nebraska
Northwell Health
Lake Success, New York
West Cancer Center & Research Institute
Germantown, Tennessee
Henry-Joyce Cancer Clinic
Nashville, Tennessee
The University of Texas MD Anderson Cancer Center
Houston, Texas
Utah Cancer Specialists Cancer Center
Salt Lake City, Utah
Fred Hutchinson Cancer Research Center
Seattle, Washington
University of Wisconsin
Madison, Wisconsin
Sanatorio Finochietto
CABA, Argentina
Prince of Wales Hospital-Randwick-66496
Randwick, New South Wales, Australia
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
Cliniques Universitaires Saint-Luc
Brussels, Belgium
UZ Leuven
Leuven, Belgium
Arthur J. E. Child Comprehensive Cancer Centre
Calgary, Alberta, Canada
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Sun Yat-Sen University Cancer Center
Guangzhou, China
University Hospital Olomouc
Olomouc, Czechia
Copenhagen University Hospital, Rigshospitalet
København Ø, Denmark
CTR Leon Berard
Lyon, France
CTR Eugène Marquis
Rennes, France
Helios Klinikum Berlin-Buch
Berlin, Germany
Universitätsklinikum Tübingen
Tübingen, Germany
Clinexpert Gyongyos
Gyöngyös, Hungary
Sourasky Medical Center
Tel Aviv, Israel
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy
Istituto Oncologico Veneto IRCCS
Padova, Italy
National Hospital Organization Kyushu Cancer Center
Fukuoka, Fukuoka, Japan
Kyushu University Hospital
Fukuoka, Fukuoka, Japan
Kanagawa Cancer Center
Kanagawa, Yokohama, Japan
Tohoku University Hospital
Miyagi, Sendai, Japan
Okayama University Hospital
Okayama, Okayama, Japan
Osaka International Cancer Institute
Osaka, Osaka, Japan
National Cancer Center Hospital
Tokyo, Chuo-ku, Japan
Oslo Universitetssykehus HF, Radiumhospitalet
Oslo, Norway
Oncology Center-Maria Sklodowska-Curie Institute
Warsaw, Poland
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.